Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men.
BACKGROUND: The quadrivalent human papillomavirus vaccine (qHPV) is FDA-approved for use in males 9 to 26 years old to prevent anogenital condyloma. The objective of this study is to determine if qHPV is effective at preventing anal condyloma among men who have sex with men (MSM) aged 26 years and o...
Main Authors: | Kristin A Swedish, Stephen E Goldstone |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3979673?pdf=render |
Similar Items
-
Awareness and acceptance of HPV vaccination for condyloma acuminata among men who have sex with men in China
by: Xuqi Ren, et al.
Published: (2022-11-01) -
The prevalence of anal human papillomavirus among young HIV negative men who have sex with men
by: Zou Huachun, et al.
Published: (2012-12-01) -
Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam
by: Le Anh Tuan, MD, PhD, et al.
Published: (2021-11-01) -
Anal human papillomavirus genotype distribution and its associations with abnormal anal cytology among men who have sex with men
by: I Ketut Agus Somia, et al.
Published: (2022-12-01) -
Anal HPV infection in Slovenian men who have sex with men
by: Milošević Miloš, et al.
Published: (2010-12-01)